Prieur Marc sold $477K of ATR

Prieur Marc (Segment President) sold 3,500 shares of APTARGROUP, INC. (ATR) at an average of $136.26 ($136.23–$137.10, $0.48M total) across 2 trades on 2026-08-04.

Original reporting
SEC EDGAR · Prieur Marc
Published Aug 5, 2026, 9:50 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 5, 2026, 9:52 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ATR
Neutral
high confidence
Mentioned
$ATR
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ATRNeutralLow
01

Why it matters

Insider open-market sales can modestly affect sentiment, but this filing does not include new guidance, earnings, contracts, or regulatory actions.

02

Market read

Traders may note the insider sale as a small sentiment datapoint, but it is unlikely to drive a durable repricing without additional catalysts.

03

What to watch

No 10b5-1 plan is cited, but the filing does not provide intent, tax context, or whether other insiders are selling/buying around the same window.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-05 after-hours; sale executed 2026-08-04

Background

The article is an SEC Form 4 insider transaction disclosure for AptarGroup, Inc. (ATR).

Company-level read

Ticker impact

$ATRNeutralHigh confidence
Context

Form 4 shows insider Prieur Marc sold about $477K of ATR shares on 2026-08-04 at roughly $136.23 to $137.10 per share.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and typically fades unless repeated or paired with other disclosures.

Evidence & confidence

The filing is a Form 4 transaction detail without accompanying guidance, operational updates, or regulatory/legal developments. Insider sales are common and often not predictive absent additional context.

Market effects

No sector read-through; this is company-specific insider trading disclosure.

None indicated.

None indicated.

Counterpoint

The sale could be for diversification or personal liquidity needs, especially given the modest dollar value relative to a large-cap and the lack of any accompanying negative company news.

Key entities

  • AptarGroup, Inc.

    Company whose insider transaction is disclosed on Form 4.

  • Prieur Marc

    Segment President who sold shares in open-market transactions.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ATRHighAI 8/10

Aptar Q3 2026 slides: broad growth, strong Pharma pipeline

AptarGroup (NYSE:ATR) reported Q3 2026 sales of $1.019B, up 6% YoY, with adjusted EPS of $1.52 beating estimates. Growth was seen across all segments, but margins were pressured. The Pharma segment grew 2% reported, 1% core, while Beauty grew 9% reported, 8% core, and Closures grew 11%. Management expects Q4 adjusted EPS of $1.39-$1.47, up 17% YoY.

$ATRMed

AptarGroup Inc (ATR) (Q3 2026) Earnings Call Highlights: Core Sales Grow 5% as Pharma

AptarGroup Inc (ATR) reported Q3 2026 core sales growth of 5% across all segments, with Pharma, Beauty, and Closures up 8%, 8%, and 11% respectively. Adjusted EPS was $1.52, down 6% YoY. Pharma growth was impacted by emergency medicine destocking, expected to affect full-year sales by $65M. Beauty and Closures margins declined due to operational challenges. CEO Gael Touya outlined plans for multi-year transformation in Beauty and reiterated long-term growth targets for Pharma.

$ATRMedAI 8/10

What AptarGroup (ATR) Said on Its Q3 Earnings Call

AptarGroup (ATR) reported Q3 earnings, highlighting growth in beauty, closures, and pharma sectors. Beauty core sales rose 8%, while closures saw 11% growth. Pharma developments include collaborations and acquisitions. The company recorded a $61.2M charge related to its Russian subsidiary. ATR forecasted Q4 adjusted EPS of $1.39-$1.47, up 17% YoY. Full-year capex is expected at $260M-$280M. Virginie Maes will lead Aptar Pharma starting January 1.